Category: Abstracts
- Hideto Nishimura, Junnichi Ishii, Hiroshi Takahashi, et al
In conclusion, similar to hs-cTnT, cMyC at admission may be a potent, independent predictor of 6-month all-cause mortality in patients without ACS treated at medical CICUs, and their prognostic abilities may be comparable. Combining cMyC or hs-cTnT with NT-proBNP may substantially improve early risk stratification of this population.
- M. Yildirim, C. Salbach, B.R. Milles et al
Incorporating cMyBP-C and hs-cTnT - effectively rules out AMI, showing non-inferiority to hs-cTnT-only-based rapid rule-out algorithms and offers a promising alternative, potentially enhancing clinical decision-making in emergency settings.
- E Riveland, A Ushakova, T Valborgland, et al
Changes in levels of the novel biomarker cMyC were significantly associated with hs-cTnI plasma levels in patients with
symptomatic chronic HFrEF during a structured 12-week exercise training program. Being more sensitive may indicate a role as a future
marker of subclinical myocardial damage.
- Tom Gilbey, Liam Couch, Bashir Alaour, et al
When compared with high-sensitivity troponin, cMyC concentrations showed greater interindividual variability and rose to a level that was statistically distinguishable from baseline at the 3 hour timepoint, as opposed to 5 hours for the more established biomarker, high-sensitivity troponin.
- Bashir Alaour, Thomas E Kaier, Rasmus Bo Hasselbalch, et al
We have previously shown that significant circadian oscillations exist for cardiac troponin T (cTnT) but not for cardiac troponin I (cTnI).
Cardiac myosin-binding protein C (cMyC) is a novel protein biomarker of myocardial injury with a promising role in the diagnosis and risk stratification of acute myocardial injury.
In this study, we examine and compare the diurnal variation of cMyC with cTnT/I.
- Bashir Alaour, Yu Jin Chung, Thomas Edward Kaier et al
Phosphorylation and fragmentation pattern of cMyC are dependent on the type of myocardial injury and might aid the differentiation between Type-1 and non-Type-1 AMI.